Antibiotics present and future  by Altman, S.
FEBS Letters 588 (2014) 1–2journal homepage: www.FEBSLetters .orgReviewAntibiotics present and future0014-5793/$36.00  2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.febslet.2013.10.048
E-mail address: sidney.altman@yale.eduS. Altman
Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, CT 06520, USAa r t i c l e i n f o a b s t r a c tArticle history:
Received 27 September 2013
Accepted 31 October 2013
Available online 16 November 2013
Edited by Wilhelm Just
Keywords:
Malaria
Drug resistant bacteria
RNase PHere we make a brief survey of the present state of antibiotic research and use. We also describe a
novel antibiotic that contains a basic peptide covalently bound to a morpholino oligonucleotide.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.Antibiotics that are most frequently employed today are small
molecules, i.e., molecular weight approximately 500, and their
users are very susceptible to drug resistance. Many newer technol-
ogies have been developed that present drugs of a much larger
molecular weight than the ones available now. A discussion of
one of these new compounds and technologies that allow the use
of drugs that are much more resistant will follow, but ﬁrst it is
appropriate to discuss why the novel methods and drugs are not
being developed rapidly on a larger scale.
Many large pharmaceutical companies make new versions of
drugs now by using the core structure of a molecule that could be
effective and attaching it to various groups to make the ﬁnished
compound of a drug. These high throughput or combinatorial meth-
ods give one the ability to test thousands of compounds quickly. The
problemofdrug resistancewill bedelayed if oneof thesecompounds
is employedbut itwill returnwithin a fewyears. This is not adequate
intellectually and reﬂects the inability of the pharmaceutical indus-
try tovitalize its researchmethods. Itmightbeargued that thecostof
investing in a very new technology and then developing a product is
beyond the stringent proﬁt requirements of these large companies.
While those budgetary constraints might be real they clearly show
that the industry is lagging behind the need for relentless innova-
tion. Some start-up companies and individual researchers are push-
ing ahead with their own new ways of approaching this problem.
Currently, antibiotics are small molecules that are susceptible
to one mutation that will change drug sensitivity to drug resis-
tance. Using nucleic acids as part of a novel compound will remove
this problem. The EGS technology, in which a piece of RNA, or a
derivative of it, is put inside a cell and is complementary in
Watson–Crick fashion to an RNA inside the cell, can sustain threemutations and is still functional. Four mutations, in the piece of
RNA that is about 15 nts long, will destroy its function. The target
pathogenic RNA can be any molecule whose sequence is known,
and most RNAs do have their sequence known, and the attacking
EGS RNA can have its sequence changed immediately if necessary
to shift its target very quickly. Furthermore, attaching a speciﬁc
basic peptide, 22 amino acid residues long, enable the ﬁnished
compound to penetrate many different bacterial cells, Gram nega-
tive and Gram positive [1], and red blood cells infected with the
malarial parasite, Plasmodium falciparum [2]. These compounds
can also invade human cells in tissue culture.
The details of the new compounds are sketched in Fig. 1. The
diagram is of a compound that will attack the gyrase A gene of
Escherichia coli, the gene product of which is essential for survival
of the bacterium. Note that the piece of RNA is actually a morpho-
lino oligonucleotide that has a morpholino sugar and a backbone
that is not the usual phosphoester backbone. It is highly resistant
to degradative nucleases in bacteria growth medium or in the
growth medium of tissue culture cells. In fact, in experiments car-
ried out in infected red blood cells, some of the L-arginine residues
are substituted with D-arginines in ﬂuorescence experiments.
The sequence in thegyraseAgeneofE. coli that is the target for the
compound shown in Fig. 1 is also highly conserved among many
bacteria. Some of the bacteria we studied are different in three
nucleotides, not contiguous with each other, and they are good
targets for this particular compound. Table 1 shows a list of several
bacteria that we examined [1,3]. The viability of these bacteria has
been tested after six hours exposure to the compound in simple
experiments in which the compound is added to the growing
bacteria in culture. Other genes have also been tested with
compounds in which the base sequence has been altered. These
include the lac and amp genes.
Fig. 1. Schematic diagram of the covalent synthesis of a basic peptide and a morpholino oligonucleotide [1].
Table 1
Viability of bacteria after treatment with an antibiotic conjugate after 6 h of growth in
liquid growth medium [3].
Bacterium Conjugate Conc. (lM) Viability
E. coli AB2-gyr313-14 0.5 106
S. typhimurium gyr313-14 0.5 103
B. subtilis gyr313-14 0.5 6  106
P. syringae gyr313-14 2 6  102
Acinetobacter gyr313-11 0.5 3  103
K. pneumoniae gyr313-14 0.5 4  105
S. aureus Sa gyr313-14 5 7.5  104
Enterobacter AB1-CAT 5 0.02
Enterobacter AB2-gyr313-11 5 0.08
S. aureus AB2-gyr313-14 1 0.30
E. faecalis AB2-gyr313-11 2 0.03
M. marinum AB1-mmbla 1 0.27
M. marinum AB1-gyr313 1 0.12
Conjugate AB1-gyr313-14 has a basic peptide attached covalently to a morpholino
oligonucleotide that targets the E. coli gyrA mRNA. AB2 is the same peptide that
lacks a cysteine residue at its C-terminal end. Sa-gyr313-14 targets speciﬁcally the
S. aureus gyrA mRNA.
Fig. 2. Effect of antibiotic conjugates in P. falciparum-infected erythrocytes [2]. (A)
Effect of treatment with antibiotic conjugates that target either the P. falciparum
gyrA (triangles) or the E. coli bla (penicillin resistance) (hollow diamonds) mRNAs
on the growth of the parasite during its intra-erythrocytic life cycle. Growth assays
were performed using a SYBR Green-I assay after culturing parasites for 72 h at
37 C in the presence of the conjugates. (B) Effect of PlfgyrA conjugate on PlfgyrA
mRNA levels. PlfgyrA mRNA levels of PlfgyrA in the absence (black bars) or presence
(gray bars) of the conjugate were measured using qRT-PCR. The Plf-b-actin gene
was used as an internal control.
2 S. Altman / FEBS Letters 588 (2014) 1–2The development of Plasmodium falciparum in red blood cells is
also shown in Fig. 2. The compound, again altered to match the P.
falciparum gyrase A gene, is effective in reducing the development
of the parasite markedly as the ﬁgure indicates [2]. Other strains of
the parasite that resistant to drugs used currently are equally sen-
sitive to the administration of the drug is tissue culture. Two more
P. falciparum genes have also been tested recently with great
success.
A practical example of the use of our compound involved its
curing of Staphylococcus aureus infection of puncture wounds in
the backs of mice [4]. One application of the compound a day after
infection led to curing of the wounds ten days later. A control com-
pound worked much less well.
One important aspect of the elimination of drug resistance in
humans is the careless habit of prescribing drugs when they are
not used, or of prescribing them without reasonable instructions.
We hope that physicians will be more rigorous in their habits in
this regard.
This year 7% of all deaths in England were due to drug resistant
infections and the number for the USA was 23000 deaths out of
2 million made ill due to this phenomenon. Each year from 1 to
1.5 million people die of malaria. Adding to the cost of an antibiotic
from let us say 50 cents per dose (US dollars) to $2 or $3 dollars for
any of the newer high molecular weight compounds, at fewer
doses required now for therapy would be an extremely wise
investment by governments in many countries, especially those
in southeast Asia, and would be a boon to drug makers and cer-
tainly a promise for the future of the pharmaceutical industry.
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